Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.03), Briefing.com reports. During the same period in the prior year, the company posted ($0.66) earnings per share. The firm’s revenue for the quarter was down 99.3% compared to the same quarter last year.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up $1.38 during trading on Friday, reaching $28.00. The company’s stock had a trading volume of 2,367,929 shares, compared to its average volume of 1,230,941. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.32.

Several research firms recently commented on ADMS. BidaskClub cut Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 17th. ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Noble Financial reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 target price on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 20th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $33.00 target price (up previously from $29.00) on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $39.50.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/03/adamas-pharmaceuticals-inc-adms-posts-earnings-results-misses-estimates-by-0-03-eps.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.